Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Other: 2021-2025

Historic Receivables - Other for Amphastar Pharmaceuticals (AMPH) over the last 2 years, with Sep 2025 value amounting to $500,000.

  • Amphastar Pharmaceuticals' Receivables - Other rose 25.00% to $500,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $500,000, marking a year-over-year increase of 25.00%. This contributed to the annual value of $200,000 for FY2024, which is N/A change from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Receivables - Other stood at $500,000 for Q3 2025, which was down 0.00% from $500,000 recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Receivables - Other's 5-year high stood at $2.5 million during Q3 2021, with a 5-year trough of $200,000 in Q3 2022.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Receivables - Other value was $300,000 (recorded in 2024), while the average stood at $325,000.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Receivables - Other crashed by 92.00% in 2022 and then spiked by 66.67% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Receivables - Other (Quarterly) stood at $2.5 million in 2021, then crashed by 92.00% to $400,000 in 2022, then reached $200,000 in 2023, then soared by 50.00% to $200,000 in 2024, then grew by 25.00% to $500,000 in 2025.
  • Its last three reported values are $500,000 in Q3 2025, $500,000 for Q2 2025, and $200,000 during Q1 2025.